ORPHA:91135
Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency
Also known as: PXE-like syndrome · Pseudoxanthoma elasticum-like syndrome
Publications
61
40.6th percentile
Trials
0
Interventional, condition-specific
Researchers
272
Distinct authors in sample
Gene link
GGCX
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic skin disease characterized by severe skin laxity affecting the trunk and limbs.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0012570
- MeSH:C563654
- OMIM:610842
- UMLS:C1835813
Additional Mondo synonyms (1)
pseudoxanthoma elasticum-like syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — GGCX
- LiteraturePresent
61 matched papers (25 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GGCX).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
61
61 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
61 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
25 in the last 10 years · high confidence · 40.6th percentile (publications denominator)
Phrase hits: 61 · MeSH hits: 0
Who's working on it?
272
Distinct author names in 61 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Martin L8 papers · 2021
PXE Reference Center (MAGEC Nord), Angers University Hospital, Angers, France.
Papers in Europe PMC - 02Vanakker OM8 papers · 2022
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Papers in Europe PMC - 03Stafford DW5 papers · 2021
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Papers in Europe PMC - 04Tie JK5 papers · 2021
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Electronic address: jktie@email.unc.edu.
Papers in Europe PMC - 05Aessopos A4 papers · 2004Papers in Europe PMC
- 06De Paepe A4 papers · 2012Papers in Europe PMC
- 07Schurgers LJ4 papers · 2021
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.
Papers in Europe PMC - 08Vermeer C4 papers · 2016
R&D Group VitaK, Maastricht University, Maastricht, The Netherlands.
Papers in Europe PMC - 09Arányi T3 papers · 2021
Research Center for Natural Sciences, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary.
Papers in Europe PMC - 10Farmakis D3 papers · 2004
First Department of Internal Medicine, University of Athens, Medical School, Laiko General Hospital, Athens, Greece. dfarm1@panafonet.gr
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07269288·NOT YET RECRUITING·The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
Conditions: Acute Ischemic Stroke·Matched via recall expansion
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency" OR "PXE-like syndrome" OR "Pseudoxanthoma elasticum-like syndrome"
MeSH descriptor terms unioned into the query: Pseudoxanthoma Elasticum-Like Disorder with Multiple Coagulation Factor Deficiency
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency" OR "PXE-like syndrome" OR "Pseudoxanthoma elasticum-like syndrome" OR "Pseudoxanthoma Elasticum-Like Disorder with Multiple Coagulation Factor Deficiency" OR "GGCX"
Recall-expansion terms: GGCX
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:57:09.196Z